Tasly Pharmaceutical Group Co Ltd Cash Flow Quality Index
Tasly Pharmaceutical Group Co Ltd cash flow quality index. Tasly Pharmaceutical Group Co Ltd (600535) has a Cash Flow Quality Index of 4.56x as of December 2025. Operating cash flow of CN¥552.13 Million exceeds net income of CN¥121.03 Million, indicating high earnings quality where cash backs reported profits. See 600535 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Tasly Pharmaceutical Group Co Ltd (2001–2025)
Cash flow quality index of Tasly Pharmaceutical Group Co Ltd from 2001 to 2025. Historical Cash Flow Quality Index for Tasly Pharmaceutical Group Co Ltd across 25 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore 600535 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Tasly Pharmaceutical Group Co Ltd Cash Flow Quality Index by Year (2001–2025)
Tasly Pharmaceutical Group Co Ltd cash flow quality index by year from 2001 to 2025. Year-by-year earnings quality comparison for Tasly Pharmaceutical Group Co Ltd. For the full cash flow conversion analysis, see Tasly Pharmaceutical Group Co Ltd cash flow conversion.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.29x | CN¥1.42 Billion | CN¥1.11 Billion | ▼ -45.0% |
| 2024 | 2.35x | CN¥2.01 Billion | CN¥859.06 Million | ▼ -7.4% |
| 2023 | 2.53x | CN¥2.58 Billion | CN¥1.02 Billion | ▼ -91.4% |
| 2022 | 29.31x | CN¥2.29 Billion | CN¥77.97 Million | ▲ +2419.1% |
| 2021 | 1.16x | CN¥2.80 Billion | CN¥2.41 Billion | ▼ -26.9% |
| 2020 | 1.59x | CN¥1.79 Billion | CN¥1.13 Billion | ▼ -5.0% |
| 2019 | 1.67x | CN¥1.68 Billion | CN¥1.00 Billion | ▲ +78.5% |
| 2018 | 0.94x | CN¥1.49 Billion | CN¥1.59 Billion | ▲ +260.0% |
| 2017 | -0.59x | CN¥-822.56 Million | CN¥1.40 Billion | ▼ -162.0% |
| 2016 | 0.95x | CN¥1.15 Billion | CN¥1.22 Billion | ▲ +324.1% |
| 2015 | 0.22x | CN¥340.00 Million | CN¥1.52 Billion | ▼ -47.5% |
| 2014 | 0.43x | CN¥616.76 Million | CN¥1.45 Billion | ▲ +43.3% |
| 2013 | 0.30x | CN¥346.17 Million | CN¥1.17 Billion | ▼ -43.1% |
| 2012 | 0.52x | CN¥413.31 Million | CN¥792.08 Million | ▲ +147.1% |
| 2011 | 0.21x | CN¥135.14 Million | CN¥639.96 Million | ▼ -75.4% |
| 2010 | 0.86x | CN¥395.05 Million | CN¥459.43 Million | ▼ -30.5% |
| 2009 | 1.24x | CN¥400.39 Million | CN¥323.63 Million | ▲ +19.0% |
| 2008 | 1.04x | CN¥260.21 Million | CN¥250.38 Million | ▼ -23.6% |
| 2007 | 1.36x | CN¥221.55 Million | CN¥162.97 Million | ▲ +106.7% |
| 2006 | 0.66x | CN¥140.56 Million | CN¥213.70 Million | ▼ -40.4% |
| 2005 | 1.10x | CN¥214.90 Million | CN¥194.60 Million | ▼ -5.1% |
| 2004 | 1.16x | CN¥203.27 Million | CN¥174.63 Million | ▲ +180.6% |
| 2003 | 0.41x | CN¥59.00 Million | CN¥142.22 Million | ▼ -76.4% |
| 2002 | 1.76x | CN¥206.22 Million | CN¥117.27 Million | ▲ +116.8% |
| 2001 | 0.81x | CN¥83.77 Million | CN¥103.29 Million | — |